eglumegad   Click here for help

GtoPdb Ligand ID: 1393

Synonyms: LY354740
PDB Ligand
Compound class: Synthetic organic
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 2
Topological polar surface area 100.62
Molecular weight 185.07
XLogP -3.39
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)C1C2C1C(CC2)(N)C(=O)O
Isomeric SMILES OC(=O)[C@H]1[C@H]2[C@@H]1[C@](CC2)(N)C(=O)O
InChI InChI=1S/C8H11NO4/c9-8(7(12)13)2-1-3-4(5(3)8)6(10)11/h3-5H,1-2,9H2,(H,10,11)(H,12,13)/t3-,4-,5-,8-/m0/s1
InChI Key VTAARTQTOOYTES-RGDLXGNYSA-N
No information available.
Summary of Clinical Use Click here for help
Eglumegad (LY354740) is a research drug being investigated for efficacy in the treatment of anxiety [3,8] and drug addiction [5].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
A glutamate derivative, eglumegad is a selective agonist for the group II metabotropic glutamate receptors (mGluR2/3) [1,9]. These receptors reduce the activity of postsynaptic potentials in the cortex by inhibiting the release of glutamate and GABA. This class of drug represents a novel mechanism of action in treating anxiety, as such compounds appear to have no reproducible interaction with dopamine D2 receptors, which are an established drug target in psychosis.